Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESRS11-92Cat.No.:HY-116087CASNo.:1467047-25-1分?式:C??H??N?O?分?量:352.47作?靶點(diǎn):Ferroptosis作?通路:Apoptosis儲(chǔ)存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:250mg/mL(709.28mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.8371mL14.1856mL28.3712mL5mM0.5674mL2.8371mL5.6742mL10mM0.2837mL1.4186mL2.8371mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(5.90mM);Suspendedsolution;Needultrasonic2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.90mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性SRS11-92?種Ferrostatin-1(Fer-1)類似物，?種有效的鐵死亡(ferroptosis)抑制劑。SRS11-92抑制Erastin誘導(dǎo)的HT-1080?纖維?瘤細(xì)胞鐵致細(xì)胞死亡(EC50=6nM)。體外研究SRS11-92fullyprotectsoligodendrocytes(OLs)fromcystinedeprivationwhentestedat100nM.SRS11-92rescuesprimaryhumanfibroblastsfromdeathinducedbyfrataxinknock-down[2].體內(nèi)研究SRS11-92,usedat500nM,isefficaciousinprotectinghumanandmousecellularmodelsofFriedreichataxia(FRDA)treatedwithferricammoniumcitrate(FAC)andaninhibitorofglutathionesynthesis(BSO),whereascaspase-3inhibitorsfailtoshowsignificantbiologicalactivity[2].REFERENCES[1].SkoutaR,etal.Ferrostatinsinhibitoxidativelipiddamageandcelldeathindiversediseasemodels.JAmChemSoc.2014;136(12):4551-4556.[2].CotticelliMG,etal.FerroptosisasaNovelTherapeuticTargetforFriedreich'sAtaxia.JPharmacolExpTher.2019;369(1):47-54.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel: